Citius Oncology appoints Jonathan Peri as new independent board member to strengthen governance.

Citius Oncology has appointed Jonathan Peri, Ph.D., J.D., as an independent director on its Board, expanding it to nine members. Peri brings extensive experience in higher education, law, and corporate governance, which the company expects will enhance its strategic oversight as it grows following the commercial launch of its cancer drug LYMPHIR. This appointment supports Citius Oncology's mission to deliver innovative therapies for cutaneous T-cell lymphoma and strengthen its legal, regulatory, and financial governance.